Effect of Ocrelizumab in Blood Leukocytes of Patients With Primary Progressive MS

Abstract

ObjectiveTo analyze the changes induced by ocrelizumab in blood immune cells of patients with primary progressive MS (PPMS).MethodsIn this multicenter prospective study including 53 patients with PPMS who initiated ocrelizumab treatment, we determined effector, memory, and regulatory cells by flow cytometry at baseline and after 6 months of therapy. Wilcoxon matched paired tests were used to assess differences between baseline and 6 months' results. p Values were corrected using the Bonferroni test.ResultsOcrelizumab reduced the numbers of naive and memory B cells (p < 0.0001) and those of B cells producing interleukin (IL)-6, IL-10, granulocyte-macrophage colony-stimulating factor (GM-CSF), and tumor necrosis factor-alpha (TNFα) (p < 0.0001 in all cases). By contrast, the proportions of plasmablasts and B cells producing GM-CSF and TNFα increased significantly, suggesting the need for treatment continuation. We also observed a decrease in CD20+ T-cell numbers (p < 0.0001) and percentages (p < 0.0001), and a clear remodeling of the T-cell compartment characterized by relative increases of the naive/effector ratios in CD4+ (p = 0.002) and CD8+ (p = 0.002) T cells and relative decreases of CD4+ (p = 0.03) and CD8+ (p = 0.004) T cells producing interferon-gamma. Total monocyte numbers increased (p = 0.002), but no changes were observed in those producing inflammatory cytokines. The immunologic variations were associated with a reduction of serum neurofilament light chain (sNfL) levels (p = 0.008). The reduction was observed in patients with Gd-enhanced lesions at baseline and in Gd− patients with baseline sNfL >10 pg/mL.ConclusionsIn PPMS, effector B-cell depletion changed T-cell response toward a low inflammatory profile, resulting in decreased sNfL levels.

Role of B Cell Profile for Predicting Secondary Autoimmunity in Patients Treated With Alemtuzumab

“…When exploring the ability of these cells to predict secondary autoimmunity at baseline, we found that this was not the case in patients treated previously with natalizumab, who mostly presented a lower percentage of plasmablasts. This agrees with previous data showing that natalizumab and no other disease modifying drugs diminish the percentages of plasmablasts in blood (14,15,24).…”

Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies

“…We suggest that this failure is related to depletion of naive and memory B lymphocytes that occurs under ocrelizumab treatement. 22 These cells are responsible for the generation of antibody production, and therefore their depletion harms humoral protection.…”

Predictors of Ocrelizumab Effectiveness in Patients with Multiple Sclerosis

“…CD20 + T cells have been found to be increased in MS patients [26], representing almost 20% of all CD20 + expressing cells [27]. It has been recently showed that ocrelizumab reduces CD20 + T cells after 6 months of treatment [28], in line with similar findings found during treatment with rituximab [29]. We showed that patients with persistent early inflammatory activity during the first year of treatment had higher levels of CD8 + cells at 6-month FU as compared with stable patients.…”